Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05178888 · ClinicalTrials.gov registry record · Phase 1
Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16)
A Phase 1 study, sponsored by Mirati Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT05178888 is a Phase 1 study that has completed, run by Mirati Therapeutics. The registered enrollment target is 11 participants.
The verdict
NCT05178888, a Phase 1 study, has completed, sponsored by Mirati Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
This study will evaluate the safety and clinical activity of MRTX849 (adagrasib) in combination with palbociclib in patients with advanced solid tumor malignancies with KRAS G12C mutation.
Interventions
- DRUG Palbociclib
- DRUG MRTX849
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2022-01-20 |
| Est. Completion | 2024-12-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05178888
The ClinicalTrials.gov registry entry for NCT05178888 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mirati Therapeutics, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Palbociclib is the first listed.
NCT05178888 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05178888 about?
NCT05178888 is a clinical study titled "Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16)". This study will evaluate the safety and clinical activity of MRTX849 (adagrasib) in combination with palbociclib in patients with advanced solid tumor malignancies with KRAS G12C mutation.
What is the current status of trial NCT05178888?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2022-01-20. Estimated completion is 2024-12-30.
What interventions are being tested in trial NCT05178888?
The interventions under investigation include: Palbociclib (DRUG), MRTX849 (DRUG).
Who is sponsoring clinical trial NCT05178888?
This trial is sponsored by Mirati Therapeutics, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.